Treatment With CSL312 in Adults With Coronavirus Disease 2019 (COVID-19)
Public ClinicalTrials.gov record NCT04409509. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2, Multicenter, Double Blind, Randomized, Placebo-Controlled Study to Evaluate CSL312 in Coronavirus Disease 2019 (COVID 19)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a prospective, phase 2, multicenter, randomized, double blind, placebo controlled, parallel group study to assess the safety and efficacy of CSL312 administered intravenously, in combination with standard of care (SOC) treatment, in patients with Coronavirus disease 2019 (COVID 19)
Study identification
- NCT ID
- NCT04409509
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 124 participants
Conditions and interventions
Conditions
Interventions
- Garadacimab, Factor XIIa Antagonist Monoclonal Antibody Biological
- Placebo Drug
Biological · Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 1, 2020 (Actual)
- Primary completion
- Jan 12, 2021 (Actual)
- Completion
- Jan 12, 2021 (Actual)
- Last update posted
- Jan 24, 2022
2020 – 2021
United States locations
- U.S. sites
- 14
- U.S. states
- 10
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Nova Clinical Research, LLC | Bradenton | Florida | 34209 | — |
| Theia Clinical Research, LLC | St. Petersburg | Florida | 33707 | — |
| MercyOne North Iowa Medical Center | Mason City | Iowa | 50401 | — |
| Northeast Iowa Medical Education Foundation | Waterloo | Iowa | 50702 | — |
| Lahey Hospital and Medical Center | Burlington | Massachusetts | 01805 | — |
| University of Mississippi Medical Center | Jackson | Mississippi | 39216 | — |
| Holy Name Hospital | Teaneck | New Jersey | 07666 | — |
| Inspira Health Center Vineland | Vineland | New Jersey | 08360 | — |
| Sisters of Charity Hospital/ St. Joseph's Campus | Buffalo | New York | 14225 | — |
| Carolina Institute for Clinical Research | Fayetteville | North Carolina | 28304 | — |
| Monument Health Clinical Research | Rapid City | South Dakota | 57701 | — |
| PharmaTex Research | Amarillo | Texas | 79109 | — |
| UT Health Science Center, McGovern Medical School | Houston | Texas | 77030 | — |
| Inova Alexandria Hospital | Alexandria | Virginia | 22304 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04409509, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 24, 2022 · Synced Oct 27, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT04409509 live on ClinicalTrials.gov.